Core Insights - Zealand Pharma is exploring a direct-to-patient sales model for its experimental weight-loss drug, in addition to traditional sales through insurers [1] - The CEO highlighted a shift in the market dynamics that may support this new sales approach [1] Company Strategy - The company is considering a dual-channel strategy that includes both direct-to-patient sales and traditional insurer channels [1] - This strategy aims to enhance accessibility and potentially increase the market reach of the weight-loss drug [1] Market Dynamics - The CEO's comments reflect a broader trend in the pharmaceutical industry towards more direct engagement with patients [1] - The shift in market dynamics may be influenced by changing consumer preferences and the increasing importance of patient-centric models [1]